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Extraction, Localization, and
Metabolism of Di-2-ethylhexyl Phthalate
from PVC Plastic Medical Devices
by Rudolph J. Jaeger*t and Robert J. Rubin*
The results of our studies on the extrac-
tion and disposition of three plasticizing sub-
stances which are extracted from poly(vinyl
chloride) medical devices will be reported.
The plasticizers are di-2-ethylhexyl phthalate
(DEHP), di-2-ethylhexyl adipate (DEHA),
and butylglycolyl butyl phthalate (BGBP).
DEHP extraction will be described in greater
detail, and the two other plasticizers, DEHA
and BGBP, will only be mentioned briefly.
The compound DEHP is an aromatic
diacid ester that meets the physical criteria
needed to soften and plasticize the rigid
polymer poly(vinyl chloride) (PVC). As a
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plasticizer the material is added to PVC dur-
ing manufacture and may represent between
20 and 40% of the finished weight of the
plastic. The plasticizing agent is not firmly
bound to the plastic but is in loose solution
and, as such, may be extracted by a variety
of organic solvents. Unfortunately, the plas-
ticizer is to some extent soluble in biologic
fluids such as blood and blood plasma. This
is the key to this report.
The present series of studies began with
an unknown compound isolated from a liver
perfusion system. This substance was char-
acterized as a phthalate ester and was a
metabolite of the plasticizer, BGBP. Subse-
quent investigation disclosed that yet
another type of plastic tubing also resulted
in contamination of the perfusate. The sub-
stance found in this case was not a metab-
olite, but the intact plasticizer. The results
of an experiment with this type of tubing
are shown in Figure 1. The tubing of the
liver perfusion system was assembled, and
perfusate (a blood and albumin solution)
was pumped through the tubing in the ab-
sence of a liver. An amount of the same
perfusion fluid was kept in the chamber at
370C for the entire perfusion time. This was
called noncirculated perfusion fluid. An
organic extract of both perfusates was pre-
pared, and analysis by thin-layer chromatog-
raphy was performed. As can be seen, the
sample of circulated perfusion fluid contains
DEHP while the noncirculated perfusion
fluid does not.
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FIGURE 1. Thin-layer chromatogram of perfusion
fluid (1).
We attempted further to quantify the re-
sults obtained in this first experiment and
also to determine what factor in perfusion
fluid is responsible for DEHP extraction.
Three separate perfusing solutions; saline, 4%
bovine serum albumin (BSA) and perfusate,
were pumped for 5 hr through the tubing
used in an isolated perfusion system. The
liver was omitted. It can be seen in Figure 2
that saline did not extract DEHP and was
not different from the reagent blank. The
4% BSA solution, however, did extract 0.7
mg DEHP, while perfusate extracted almost
three times as much, 2 mg DEHP. Thus, it
appears that blood in the perfusion fluid
with its additional content of cells, protein,
and lipid is better able to extract DEHP
than protein alone.
The observations that blood is capable of
extracting the plasticizer from tubing in
which it is transported led to the further
question, whether human blood is capable of
extracting DEHP from medical device tubing
in which it is circulated. Specifically, med-
ical grade poly(vinyl chloride) plastic tubing
is employed in cardiopulmonary-bypass
apparatus and in hemodialysis apparatus.
Units of outdated blood (21 days old) were
obtained from the Johns Hopkins Hospital
and Baltimore City Hospital blood banks.
The blood was circulated in the two types
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FIGURE 2. DEHP extraction by proteinaceous
solutions (1).
of medical device tubing for periods up to 8
hr. The results of these experiments are
shown in Table 1. It can be seen that after 8
hr of circulation in the Travenol hemodi-
alysis unit the DEHP content of the blood
was 9.24 mg/100 ml. However, it is also
striking that at zero time the DEHP concen-
tration was 7.75 mg/100 ml. A similar result
was obtained with cardiopulmonary bypass
tubing: at 5 hr there was 5.7 mg/100 ml; at
zero time the value was 5.04 mg/100 ml.
The reason for this initial high concentration
of DEHP is quite obvious: the units of
blood were outdated and could no longer be
used for transfusion because of age. For 21
days this blood had been stored at 40C in
Table 1. Extraction ofplasticizers from two types
ofmedical devices.a
Plasticizer
concentration,
Circulation mg/100 ml blood
Medical device time. hr DEIP DEHA
Travenol hemo- 0 7.75 0
dialysis unit
8 9.24 2.14
Travenol cardio- 0 5.04 0
pulmonary by- 2.5 5.28 2.34
pass unit
5 5.70 4.99
aData of Jaeger (1).
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of human blood occurred during storage. It
is also interesting to note that another plas-
ticizer, DEHA, was not present in the blood
that came from the blood bank, but after
circulation within the tubing. DEHA concen-
trations reached 2.14 and 4.99 mg/100 ml.
We attempted to establish the rate of
DEHP extraction from plastic blood bags. It
is more likely that blood might be contam-
inated during 21 day storage in plastic blood
bags than it would be on circulation through
plastic tubing. Therefore, units of human
blood were obtained from the Johns Hop-
kins blood bank after 7, 11, 14, and 21 days
of storage. The blood samples were analyzed
for DEHP content. Samples of blood were
also taken from units of dog blood which
had been drawn and stored in a manner
similar to that employed for human blood.
The results of this experiment (2), shown in
Figure 3, indicate that the rate of DEHP
accumulation in blood was 0.25 mg/100
ml/day over a period of 21 days of storage.
It is also apparent that dog and human
blood did not differ in their rates of extrac-
tion.
This result was examined further. A single
unit, at 14 days of storage was divided into
the following components: a triply washed
red blood cell fraction and two plasma frac-
tions, that portion of plasma with a buoyant
density D greater than 1.21, and that frac-
tion with a buoyant density of less than
1.21. As shown in Figure 4, there was very
little DEHP in triply washed red cells.
Approximately 20% of the DEHP was found
in the high-density lipoprotein fraction,
(D>1.21) but much more was contained in
the low-density or buoyant lipoprotein frac-
tion (D<1.21). This result suggests that the
lipoproteins may solubilize DEHP. However,
because the density of DEHP droplets is less
than 1.21 (0.999), at room temperature, it is
also possible that the fraction having density
less than 1.21 represents DEHP which had
floated to the surface. It is apparent, how-
ever, that the plasma fraction contains
almost all of the DEHP that was found in
whole blood.
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FIGURE 3. DEHP content of human and dog blood
stored for varying periods in poly(vinyl chloride)
blood bags (2).
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FIGURE 4. DEHP recovery from human blood and
blood fractions stored 14 days in PVC (1).
We carried our studies further and at-
tempted to evaluate the amount of DEHP
found in a fraction of whole blood, human
platelet concentrates (Table 2). Five platelet
concentrates were obtained from Johns Hop-
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platelet concentrate.a
DEHP
DEHP, Volume, concentration,
Sample mg ml mg/100 ml
Platelet button
1 0.196 0.6 32.7
2 0.185 0.5 37.0
3 0.220 0.5 44.0
4 0.191 0.4 47.8
5 0.189 0.7 27.0
Mean ± S.E.M. 37.7 ± 3.8
DEHP recovered 11.1%
Platelet-poor plasma
1 1.688 9.3 18.2
2 2.227 9.5 23.4
3 1.613 9.5 17.0
4 1.447 9.5 15.2
5 0.881 9.2 9.6
Mean ± S.E.M. 16.7 ± 2.2
DEHP recovered 88.9%
aData of Jaeger (1).
kins Hospital blood bank. The outdated
units, stored for 48 hr at room temperature
in ACD anticoagulant were kept in standard
PL-130 plastic. We determined that in the
five samples, the mean DEHP concentration
in the unwashed platelet button was 37.7 +
3.8 mg DEHP/100 ml packed platelet vol-
ume. This represented 11.1% of the total
DEHP recovered from a 10-ml aliquot. The
platelet-poor plasma was found to have a
lower DEHP concentration than the platelet
button, i.e., 16.7 ± 2.2 mg/100 ml. How-
ever, because of its much greater volume,
the platelet-poor plasma contributed 88.9%
of the total recovered DEHP. The rate of
extraction of DEHP appears to be tempera-
ture-dependent. The concenctration achieved
in platelet concentrates that had been stored
at room temperature for 2 days was signifi-
cantly greater than that ever reached in a
unit of human blood stored at 40C for 21
days.
We felt that another question should be
asked: what becomes of DEHP which might
subsequently be administered to a human?
In our initial experiments, an acacia emul-
sion of DEHP was prepared and injected
into the rat peritoneal cavity; 24 hr after
injection of the emulsion the rat was sacri-
ficed, and a midline incision made. Figure 5
shows the vicera of a rat after administration
of the emulsion. The peritoneal cavity of
this rat contained a great deal of ascitic
fluid. Also, large white masses distributed
throughout the peritoneal cavity were
evident. Histologic examination indicated
that the masses were serofibroid in nature,
containing degenerating neutrophils and
macrophages. The histopathology result
suggested that the masses originated from a
chemical peritonitis, possibly due to the
administration of a material which was irri-
tating to the peritoneal cavity. Control rats
(given 3% acacia) were found to be unaf-
fected by the vehicle.
To further clarify the fate of DEHP,
emulsions were injected (IP) into rats which
were then sacrificed at intervals after the
injection. A whole-body homogenate was
prepared, and aliquots sampled to determine
the amount of DEHP which remained in the
body after 2, 4, and 13 days. Figure 6
shows that the rate of DEHP disappearance
after interperitoneal administration was quite
slow. At 13 days, approximately 25% of the
initial injected dose still remained. This fact,
FIGURE 5. Gross pathology following intraperi-
toneal administration of DEHP (rat).
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FIGURE 6. DEHP disappearance after intraperi-
toneal administration.
coupled with the rather marked peritoneal
irritation and inflammation observed, might
suggest that di-2-ethylhexyl phthalate is
metabolically inert and irritating.
Because we found DEHP to be extracted
by perfusion fluid in the isolated perfused-
liver system we attempted to determine the
fate of the DEHP in that system. We pre-
pared perfusion fluid which contained
70-80 Mg/ml DEHP and measured the total
concentration of the system at zero time
and after 0.5 and 4.5 hr. At the end of the
perfusion the liver was removed, homog-
enized, and assayed for total DEHP content.
The result (Fig. 7) indicates that within 30
min of perfusion, 90% of the total DEHP
contained in the perfusate phase of the
system has disappeared while in the remain-
ing 4 hr an additional 9% was lost. At the
end of 4.5 hr, the perfusate was essentially
cleared of DEHP, but almost all the DEHP
was recovered from the liver. This result is
in marked contrast to our observations with
BGBP, where we found a significant amount
of metabolite in the perfusate. In the DEHP
perfusion at 4.5 hr, no trace of phthalic acid
was found. Phthalic acid would be the ex-
pected de-esterified metabolite of DEHP.
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FIGURE 7. DEPH distribution in the isolated, per-
fused rat liver.
Because of the observation of accumula-
tion by the isolated perfused liver system,
we injected 40 mg of DEHP intravenously
into two rats. The rats were sacrificed 24 hr
later and tissue concentrations of DEHP
determined. The results (Table 3) indicate
that liver and lung contain the largest total
amounts of the recovered dose. The carcass
was also found to contain large amounts of
DEHP but at a relatively low concentration.
The spleen had a higher concentration, but
only about 3% of the injected dose was
found. The other tissues contained very lit-
tle. The total amount of DEHP recovered
was 79.1% of the injected dose. In similar
experiments we were never able to find any
trace of phthalic acid in the urine. This
result might suggest that DEHP is inert in
terms of the rat's ability to metabolize it to
phthalic acid following IV injection. It is
also possible that if DEHP is metabolized, it
is converted to something other than
phthalic acid per se.
If DEHP is extracted by blood from tub-
ing and containers in which it is transported
and stored, the possibility exists that this
foreign compound may be administered to
the human either when blood is admin-
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DEPH % of
Concentration, recovered injected
Tissue mg/g or mg/ml from tissue, mg dose recovered
Liver 1.6 21.82 27.3
Lung 8.18 21.26 26.6
Carcass 0.06 16.66 20.8
Spleen 1.89 2.65 3.3
Kidney 0.08 0.26 0.3
Heart 0.08 0.14 0.2
Gut <0.01 0.12 0.2
Blooa <0.01 0.03 <0.01
Brain <0.01 0.01 <0.01
Testicle <0.01 0.01 <0.01
Feces <0.01 0.334 0.4
Total 79.1
aData of Jaeger (1).
istered, when open heart surgery is per-
formed, or when hemodialysis occurs.
Therefore, autopsy tissue from these
categories of patients was sought and DEHP
analysis performed. The results that were
obtained (2) are shown in Table 4. It is
evident from Table 4 that tissues from sever-
al persons who had exposure to PVC plastic
do contain measurable amounts of DEHP.
Notably, the first patient shown is an indi-
vidual who received blood during cardio-
pulmonary bypass. The level of DEPH was
91.5 ,ug/g dry weight in the lung, 69.5 ,ug/g
in the liver, and 25.3 ,ug/g in the spleen.
However, during the bypass itself no DEHP
was detectable in the systemic blood, a re-
sult which would suggest that some organ
efficiently removes DEHP. Tissues from
other patients sampled at autopsy similarly
did contain DEHP but never at quite the
concentration observed in the first patient.
Conversely, several patients who had been
exposed to DEHP were not found to have
DEHP in their body tissues. One patient, an
individual with a massive gunshot wound of
the abdomen, had received 63 units of blood
within a 24 hr period. From calculaticns
involving use of the linear regression slope
for DEHP extraction by blood at 4°C and
its time of storage, it was calculated that
this patient may have received 600 mg of
the plasticizing agent. A sample of systemic
100
blood taken at death was found to contain
0.28 mg DEHP/100 ml blood. Samples of
lung and liver obtained at autopsy the fol-
lowing day did not contain any DEHP. In
contrast to this, another patient in this
study, a very obese female who had pan-
creatitis, had an extremely high concentra-
tion of DEHP in her abdominal fat. 270
Ag/g. However this patient was an isolated
case, and such a result was never duplicated.
We did attempt to look for DEHP in ab-
dominal fat of other individuals exposed to
DEHP but did not find it. Also, 7 individ-
uals (6 male, and 1 female) who died as a
result of accidental causes and who were not
known to have received transfusions did not
have any DEHP in their abdominal fat. The
results suggest that the amount of DEHP
found in the female patient with pancreatitis
was unique to her disease process or treat-
ment history.
Because our results indicated that some
but not all patients had measurable amounts
of DEHP in their body tissues, we attempted
to follow one person who was to undergo
open heart surgery. This patient would pre-
sumably receive DEHP from transfusions or
from exposure to PVC tubing. Samples of
urine were obtained from the patient for 2
days before surgery and for 5 days following
surgery. The urine was acidified, extracted
with ether, and analyzed directly for
phthalic acid. It was also treated by the
method of Shaffer et al. (3), i.e., the urine
was hydrolyzed with acid and base in an
attempt to determine whether some other
form of phthalic acid was present. The re-
sults (Fig. 8) indicate that this was indeed
the case. Prior to surgery, phthalic acid was
present in the urine of this patient. How-
ever, in the period immediately following
surgery, a total phthalate equivalent of 43
mg DEHP was calculated. We calculated that
23 mg resulted from known transfusions.
The remaining 20 mg DEHP was probably
received during the 1.5 hr bypass interval. It
is apparent that not only is DEHP extracted
from -tubing by blood and transfused into
human beings, but it does appear to be
metabolized by the human. It is, however,
Environmental Health PerspectivesTable 4. DEHP content of human tissues.a,b
History no. Units of DEPH content, ,g/g dry weight DEPH in
orcode blood DEHP Abdom. blood,
(sex) History adm'd adm'd mgc Lung Liver Spleen fat mg/100 ml
51 79 27 (F) Card. pulm. bypass 18 43.8 91.5 69.5 25.3 _d NDe
139 25 14 (M) Card. pulm. bypass 4 14.0 24.5 - - - -
117 67 25 (M) Card. pulm. bypass 20 ?f 22.1 - - - -
139 93 59 (M) Card. pulm. bypass 8 128.0 17.9 - - ND
130 84 99 (M) Card. pulm. bypass 6 16.8 ND ND ND
138 60 69 (M) Card. pulm. bypass 14 ? ND ND ND ND
35 46 66 (M) Aneurism 4 22.5 21.2 ND 5.0
138 89 87 (M) Mult. transf. 20.8 - - ND
pancytopenia
139 80 10 (M) Mult. transf. ? ? 13.4 - - ND
44 66 84 (M) GI bleeding 31 ? ND ND
53 71 24 (F) Pneumonia 2 ND ND ND -
035 46 66 (F) Pancreatitis 13 ? - 270.0 -
MEC (M)g Gunshot 63 600.0 ND ND - - 0.28
7 Indiv. Accidental death Not transfused - - - ND -
(6M, 1F)
aData of Jaeger and Rubin (2).
bAssay blanks ranged from 20 to 60gg DEHP. Reproducibility was ± 10%. Blank values were subtracted from
tissue values for each analytical run and the net amount per gm of dry tissue is presented. Dry tissue weights
ranged from 1.6 to 14.9 g.
CDEHP was calculated from the known storage time of each unit transfused and the previously determined
DEHP migration rate of 0.25 mg/100 ml/day.
dNot assayed.
eNot detectable, i.e., not significantly different from the corresponding assay blank. This is equivalent to less
than 0.5-3,g/g.
fNumber of units or storage time not known.
gHomocide victim, medical examiner case, Johns Hopkins history number not recorded.
metabolized to a form other than phthalic
acid.
This latter point was studied further with
three normal subjects; myself and two other
graduate students, who donated urine sam-
ples for this study (Table 5). The urine,
treated by the method of Shaffer et al., was
found to contain amounts of phthalic acid,
as did the urine from patient RM 2 days
prior to surgery. This result would suggest
that there are some phthalate compounds to
which humans are exposed through environ-
mental routes, possibly airborne inhalation
of particles of plasticizers, its vapors, or by
direct ingestion of phthalates from food.
In conclusion, these studies have shown
that several plasticizers may be extracted
from PVC tubing by human and animal
blood. DEHP may be transfused into human
beings by high concentrations, depending on
the blood or its fraction administered.
Further, some of the plasticizer, namely
DEHP, does appear to accumulate in certain
tissues and may be recovered at death from
some, but not necessarily from all patients.
At least one individual was capable of
metabolizing the plasticizer, and normal per-
sons had such substances in their urine.
There is no information currently available
which details exactly what toxicologic haz-
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FIGURE 8. Urinary phthalate before and after open
heart surgery.
ard may result from intravenous plasticizer
exposure. Much information is conjectural,
based on studies in animals who are normal-
ly healthy and not stressed. It is our recom-
mendation that poly(vinyl chloride) plastic
formulations be developed that do not con-
tribute any extractable material. Alternatively,
plastic formulations should be found which
Table 5. Hydrolysis by the Method of Shaffer
et al. (3) for urinary "phthalic acid" content of
normal individuals.
Concentration,
Subject mg PA/100 ml
Patient RM 0.48
RJJ 0.36
JK 0.74
JH 1.29
do not contain any additive and as such, will
not contribute any material to blood or its
fractions that are stored or transported in
them.
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